A multicentre study assessed toxicity and survival end points following dose-escalated prostate stereotactic body radiotherapy (SBRT) in 309 patients with low-risk or intermediate-risk prostate cancer. At a median follow-up period of 61 months, rates of grade 3 or higher genitourinary adverse events (AEs) were low (1.3%), and no grade 4 or 5 AEs occurred. The 5-year overall survival and biochemical disease-free survival compared favourably to historical controls.